Table 3.

BC Outcomes in HL Survivors and Matched Patients With Sporadic BC

Event	No. at Risk	No. With Event	Adjusted HR*	95% CI	P
Local/regional failure
HL survivors	248	32	0.94	0.51 to 1.74	NS
Patients with sporadic BC	708	86	Reference
Metastatic failure
HL survivors	248	45	1.49	0.82 to 2.71	NS
Patients with sporadic BC	708	137	Reference
Metachronous contralateral tumor
HL survivors	189	29	4.31	1.69 to 10.99	< .01
Patients with sporadic BC	699	33	Reference
Death as a result of BC
HL survivors	253	36	1.61	0.76 to 3.42	NS
Patients with sporadic BC	741	95	Reference
Death as a result of any cause
HL survivors	253	61	1.90	1.09 to 3.32	< .05
Patients with sporadic BC	741	137	Reference

NOTE. Local-regional failure included ipsilateral, new primary tumors. Analysis of local-regional failure and analysis of metastatic failure excluded women who presented with distant disease at or within 14 days of initial diagnoses. Analysis of metachronous contralateral disease excluded women who had synchronous bilateral disease at BC diagnosis or prophylactic contralateral mastectomy.

Abbreviations: BC, breast cancer; HL, Hodgkin's lymphoma; HR, hazard ratio; NS, not statistically significant.

^*HRs were adjusted for BC stage at diagnosis, axillary lymph node involvement, laterality at diagnosis, type of surgery, surgical margin status, menopausal status, family history of BC in a first-degree relative, whether BC was screen detected, receipt of radiation therapy for BC, receipt of chemotherapy for BC, and receipt of hormonal therapy for BC.